---
document_datetime: 2025-06-19 12:13:29
document_pages: 10
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/tabrecta-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: tabrecta-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 4.7724868
conversion_datetime: 2025-12-17 09:41:16.894
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Tabrecta

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0016              | Update of sections 4.8 and 5.1 of the SmPC in order to update information on based on the results of the clinical study CINC280A2201 'GEOMETRY mono-1' and add 'body temperature increased' to the list of adverse drug reactions (ADRs) with frequency 'very common'. CINC280A2201 is a global, multi-cohort, | 13/03/2025                          |                                             | SmPC and PL                      | SmPC new text Sections 4.8 and 5.1 of the SmPC have been updated to reflect final efficacy and safety data from a global, multi- cohort, non-randomized, open-label Phase II study designed to evaluate the efficacy and safety of single-agent capmatinib in adult patients with a MET exon 14 (METex14) |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2 A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | non-randomized, open-label Phase II study designed to evaluate the efficacy and safety of single-agent capmatinib in adult patients with a MET exon 14 (METex14) skipping mutation, advanced non-small cell lung cancer (NSCLC). The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce editorial changes to the PI. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data   |            |      | skipping mutation, advanced non-small cell lung cancer (NSCLC). The results are in line with the existing data. In section 4.8, in addition to the frequencies of adverse reactions being slightly adjusted, the frequency of the adverse reaction 'rash' was changed from 'common' to 'very common'. Also, the preferred term 'body temperature increased' has been included in the grouped term of 'pyrexia'. In section 5.1 , the upper limit of the 95% CI of median DOR was changed from 'not estimable' to 27.6 months. For more information, please refer to the Summary of Product Characteristics.   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0017/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                   | 07/02/2025 | SmPC |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| in the manufacturing process B.II.b.3.a - Change in the the finished or intermediate in the manufacturing process B.II.b.4.b - Change in the size ranges) of the finished down to 10-fold B.II.b.4.a - Change in the size ranges) of the finished compared to the originally B.II.b.5.z - Change to in-process applied during the manufacture product - Other variation B.II.b.5.z - Change to in-process applied during the manufacture product - Other variation B.II.e.1.a.1 - Change in finished product - Qualitative composition - Solid pharmaceutical B.II.e.2.b - Change in the and/or limits of the immediate finished product - Addition parameter to the specification test method B.II.b.1.e - Replacement manufacturing site for the manufacturing operation(s) release, batch control, packaging, for non-sterile B.II.b.2.a - Change to importer, arrangements and quality   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                     | control/testing takes place A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |     |                 |                                   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------|-----------------------------------|
| IAIN/0015           | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                     | 04/12/2024 |     | Annex II and PL |                                   |
| PSUSA/11022 /202405 | Periodic Safety Update EU Single assessment - capmatinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 28/11/2024 | n/a |                 | PRAC Recommendation - maintenance |
| IB/0014/G           | This was an application for a group of variations. B.I.b.z - Change in control of the AS - Other variation B.I.b.z - Change in control of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                         | 05/11/2024 | n/a |                 |                                   |
| IA/0013/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place | 28/08/2024 | n/a |                 |                                   |

<div style=\"page-break-after: always\"></div>

| IAIN/0011/G   | This was an application for a group of variations. B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 24/07/2024   | n/a   |                   |
|---------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-------------------|
| II/0007/G     | This was an application for a group of variations. B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation B.I.b.2.z - Change in test procedure for AS or starting material/reagent/intermediate - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other procedure (including replacement | 18/07/2024   | n/a   | changes to a test |

<div style=\"page-break-after: always\"></div>

|                     | or addition) for the AS or a starting material/intermediate B.I.b.1.f - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Change outside the approved specifications limits range for the AS                                                                                                                                             |            |     |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/11022 /202311 | Periodic Safety Update EU Single assessment - capmatinib                                                                                                                                                                                                                                                                                                                                       | 13/06/2024 | n/a | PRAC Recommendation - maintenance |
| IAIN/0010           | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                                                                                                                                                             | 08/03/2024 | n/a |                                   |
| IAIN/0008/G         | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site | 14/12/2023 | n/a |                                   |
| PSUSA/11022 /202305 | Periodic Safety Update EU Single assessment - capmatinib                                                                                                                                                                                                                                                                                                                                       | 30/11/2023 | n/a | PRAC Recommendation - maintenance |
| IA/0006             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or                                                                                                                                                                                                                                       | 12/09/2023 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|                     | intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |     |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| PSUSA/11022 /202211 | Periodic Safety Update EU Single assessment - capmatinib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 08/06/2023 | n/a | PRAC Recommendation - maintenance |
| II/0003/G           | This was an application for a group of variations. B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS B.I.a.3.b - Change in batch size (including batch size ranges) of AS or intermediate - Downscaling down to 10-fold B.I.b.2.b - Change in test procedure for AS or starting material/reagent/intermediate - Deletion of a test procedure for the AS or a starting | 02/02/2023 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| material/reagent/intermediate, procedure is already authorised B.I.a.2.a - Changes in the the AS - Minor change in of the AS B.I.a.1.z - Change in the starting material/reagent/intermediate variation B.I.a.2.a - Changes in the the AS - Minor change in of the AS B.I.b.2.c - Change in test starting material/reagent/intermediate changes to a test procedure does not have a significant quality of the AS B.I.a.3.b - Change in batch ranges) of AS or intermediate 10-fold B.I.a.3.b - Change in batch ranges) of AS or intermediate 10-fold B.I.a.3.b - Change in batch ranges) of AS or intermediate 10-fold B.I.a.2.a - Changes in the the AS - Minor change in of the AS B.I.a.4.d - Change to in-process applied during the manufacture the approved in-process   | of   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|

<div style=\"page-break-after: always\"></div>

| AS B.I.a.1.f - Change in the starting material/reagent/intermediate Changes to quality control the AS -replacement or batch control/testing takes B.I.a.4.z - Change to in-process applied during the manufacture variation B.I.a.3.b - Change in batch ranges) of AS or intermediate 10-fold B.I.a.2.a - Changes in the the AS - Minor change in of the AS B.I.b.1.z - Change in the and/or limits of an AS, material/intermediate/reagent B.I.b.1.d - Change in the and/or limits of an AS, material/intermediate/reagent significant specification an obsolete parameter) B.I.a.2.a - Changes in the the AS - Minor change in of the AS B.I.b.2.e - Change in test starting material/reagent/intermediate changes to a test procedure or addition) for the AS material/intermediate   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |            |             |                                                                                              |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------|
| II/0002   | Update of section 4.8 of the SmPC in order to add hypersensitivity to the list of adverse drug reactions (ADRs) with frequency uncommon, based on cumulative assessment of hypersensitivity cases in studies CINC280A2201, CINC280X1101, CINC280X2102, CINC280A2108, CINC280A2103 (post-DDI phase only), and CINC280A2105 (post- DDI phase only) and MAH global safety database. The Package Leaflet is updated accordingly C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 01/12/2022 | 29/11/2023 | SmPC and PL | Not applicable For more information, please refer to the Summary of Product Characteristics. |
| IAIN/0001 | B.II.g.5.a - Implementation of changes foreseen in an approved change management protocol - Requires no further supporting data                                                                                                                                                                                                                                                                                                                                                                                                               | 24/08/2022 | n/a        |             |                                                                                              |